Within the next five years, Biosimilars should take an increasingly important role as a powerful force driving down the cost of healthcare in the US and elsewhere or enabling more patients to gain access to some of the most complex biologics: eight therapies among the world’s Top 10 could face biosimilar competition, mostly in the field of inflammation.